Advertisement
GRFS vs GSK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GRFS is a Buy and GSK is a Buy.
Momentum Indicator for GRFS turns positive, indicating new upward trend
GRFS saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 64 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
GRFS moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GRFS crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +1.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRFS advanced for three days, in 195 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
The Aroon Indicator entered an Uptrend today. In 144 of 210 cases where GRFS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRFS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
GRFS broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.034) is normal, around the industry mean (-1.421). P/E Ratio (12.773) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (0.189) is also within normal values, averaging (5.738). Dividend Yield (0.042) settles around the average of (0.038) among similar stocks. GRFS's P/S Ratio (0.592) is slightly lower than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating fairly steady price growth. GRFS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
GSK's RSI Indicator recovers from oversold territory
The RSI Indicator for GSK moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 15 of the 23 cases the stock moved higher. This puts the odds of a move higher at 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on GSK as a result. In 48 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on November 04, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 29 of 46 cases over the following month. The odds of a continued upward trend are 63%.
GSK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 55%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 145 of 258 cases where GSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.715) is normal, around the industry mean (-1.421). P/E Ratio (20.988) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.036) settles around the average of (0.038) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
GRFS | GSK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 46 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 16 Undervalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 37 | |
SMR RATING 1..100 | 76 | 34 | |
PRICE GROWTH RATING 1..100 | 41 | 46 | |
P/E GROWTH RATING 1..100 | 55 | 9 | |
SEASONALITY SCORE 1..100 | 50 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GRFS's Valuation (16) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (81). This means that GRFS’s stock grew somewhat faster than GSK’s over the last 12 months.
GSK's Profit vs Risk Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for GRFS (100). This means that GSK’s stock grew somewhat faster than GRFS’s over the last 12 months.
GSK's SMR Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for GRFS (76). This means that GSK’s stock grew somewhat faster than GRFS’s over the last 12 months.
GRFS's Price Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as GSK (46). This means that GRFS’s stock grew similarly to GSK’s over the last 12 months.
GSK's P/E Growth Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for GRFS (55). This means that GSK’s stock grew somewhat faster than GRFS’s over the last 12 months.
| GRFS | GSK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 74% | 6 days ago 65% |
| Stochastic ODDS (%) | 1 day ago 73% | 1 day ago 40% |
| Momentum ODDS (%) | 1 day ago 76% | 1 day ago 62% |
| MACD ODDS (%) | N/A | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 71% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 71% | 1 day ago 58% |
| Advances ODDS (%) | 1 day ago 69% | 27 days ago 63% |
| Declines ODDS (%) | 6 days ago 76% | 1 day ago 55% |
| BollingerBands ODDS (%) | 1 day ago 82% | 1 day ago 42% |
| Aroon ODDS (%) | 1 day ago 69% | 1 day ago 56% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GRFS’s FA Score shows that 1 FA rating(s) are green while GSK’s FA Score has 1 green FA rating(s).
- GRFS’s FA Score: 1 green, 4 red.
- GSK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GRFS’s TA Score shows that 5 TA indicator(s) are bullish while GSK’s TA Score has 7 bullish TA indicator(s).
- GRFS’s TA Score: 5 bullish, 4 bearish.
- GSK’s TA Score: 7 bullish, 3 bearish.
Price Growth
GRFS (@Pharmaceuticals: Major) experienced а +2.67% price change this week, while GSK (@Pharmaceuticals: Major) price change was -1.08% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.46%. For the same industry, the average monthly price growth was +2.44%, and the average quarterly price growth was +7.11%.
Reported Earning Dates
GRFS is expected to report earnings on Mar 04, 2027.
GSK is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-1.46% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
GRFS and
Correlation & Price change
A.I.dvisor tells us that GRFS and SNY have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GRFS and SNY's prices will move in lockstep.
| Ticker / NAME | Correlation To GRFS | 1D Price Change % | ||
|---|---|---|---|---|
| GRFS | 100% | +0.91% | ||
| SNY - GRFS | 32% Poorly correlated | +0.41% | ||
| GILD - GRFS | 30% Poorly correlated | -0.67% | ||
| GSK - GRFS | 30% Poorly correlated | -1.23% | ||
| AMGN - GRFS | 30% Poorly correlated | +0.62% | ||
| BMY - GRFS | 29% Poorly correlated | +0.18% | ||
More | ||||
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.